<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127788</url>
  </required_header>
  <id_info>
    <org_study_id>FR-MYC-NI-003</org_study_id>
    <nct_id>NCT02127788</nct_id>
  </id_info>
  <brief_title>Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology</brief_title>
  <acronym>OLYMPE</acronym>
  <official_title>National, Longitudinal, Multicentre and Prospective, Observational Study of the Use of Micafungin (Mycamine®) in Antifungal Prophylaxis of Invasive Fungal Infections in Medical Practice in Haematology and Onco-haematology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma S.A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to describe the actual conditions of prescription
      of micafungin in antifungal prophylaxis in French haematological and onco-haematological
      units. The efficacy and the safety outcomes will be described.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>EORTC/MSG : European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Odds ratio and 95% CI for each identified risk factors</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of IFI, defined according to the revised EORTC/MSG criteria</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of patients treated with micafungin</measure>
    <time_frame>Day 0 (start of prophylaxis)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditions of use of micafungin</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>dose and administration pattern, temporary interruptions and treatment duration, oral treatment take-over</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of units</measure>
    <time_frame>Day 0</time_frame>
    <description>participating physicians (age, status, specialty), type of institution, location , type of unit, size of unit</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Antifungal Prophylaxis</condition>
  <condition>Haemopathy</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
    <description>Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micafungin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Micafungin</arm_group_label>
    <other_name>FK463</other_name>
    <other_name>Mycamine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized, adult patients with haemopathy or paediatric patients with haemopathy or
        solid tumor, under antifungal prophylaxis with micafungin.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.

          -  Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.

          -  Patient initiating antifungal prophylaxis with micafungin.

        Exclusion Criteria:

          -  Patient presenting documented fungal infection.

          -  Patient already included in a biomedical study impacting the care management of
             invasive fungal infection at the time of inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical and Scientific Affairs Manager, Infectious Diseases</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma S.A.S.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Angers</city>
        <zip>44933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Béziers</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Limoges</city>
        <zip>37042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Saint-Denis la Réunion</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <last_update_submitted>June 17, 2016</last_update_submitted>
  <last_update_submitted_qc>June 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haematology</keyword>
  <keyword>Micafungin</keyword>
  <keyword>Observational study</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Invasive Fungal Infection</keyword>
  <keyword>France</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Micafungin</mesh_term>
    <mesh_term>Echinocandins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

